Skip to main content

Specialty Pharmacy

  • Chiesi Farmaceutici S.p.A. acquires specialty pharmaceutical company Cornerstone Therapeutics

    CARY, N.C. — Cornerstone Therapeutics, a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, on Monday announced that its stockholders have approved, at a special stockholder meeting, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.

  • Actavis realigns corporate structure

    DUBLIN — Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 

  • Frost & Sullivan: Global biosimilars space to reach $24 billion by 2019

    LONDON — The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week. 

  • Avella Specialty Pharmacy names new CEO

    PHOENIX — Avella Specialty Pharmacy on Thursday named Rebecca Shanahan CEO. Shanahan brings more than two decades of successful leadership experience in the healthcare sector, as well as five years of service on Avella’s board of directors, to her new role. 

  • Mylan tapped as Gilead's exclusive business partner for India

    PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

    Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:

  • Cardinal Health posts Q2 revenues of $22.2 billion, increases outlook for fiscal year

    DUBLIN, Ohio — The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning. Revenue totaled $22.2 billion. The loss of the Walgreens contract totaled $5 billion. 

    But Cardinal Health is bullish regarding its future. Cardinal Health increased its outlook for the next six months, raising its non-GAAP EPS range to $3.75 to $3.85. 

  • Diplomat partners on concert series to benefit employees, community

    FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it will be partnering with The Whiting, Flint’s premier performing arts venue on bringing new entertainment opportunities to the area through the Gen X Concert Series. Performers featured will be targeted to “Generation X," or those born in the early 1960s through the early 1980s.

    In addition to the concert series, the partnership also will bring entertainment to Diplomat’s corporate headquarters. The Whiting will present local performers during select lunch periods for employees to enjoy.

  • Diplomat launches online specialty pharmacy resource targeting both patients and clinicians

    FLINT, Mich. — A new web platform has gone live from Diplomat, the nation’s largest independent specialty pharmacy reported Thursday. On Jan. 29 the company revealed a completely redesigned site that is "mobile-friendly, easy to use and primed for upcoming changes."

X
This ad will auto-close in 10 seconds